Serviscope president and CEODonald J. Southard will be leaving the independent service organizationas part of a move to refocus the company's direction. Also leavingthe Wallingford, CT, company is vice president Robert Cate. Serviscope expanded rapidly
Serviscope president and CEODonald J. Southard will be leaving the independent service organizationas part of a move to refocus the company's direction. Also leavingthe Wallingford, CT, company is vice president Robert Cate.
Serviscope expanded rapidly under Southard's tenure but hasconsumed cash almost as quickly, requiring several rounds of privateequity financing. Serviscope hopes that a change at the top willstrengthen the financial management of the company, accordingto Emile Geisenheimer, the company's chairman and a general partnerof Nazem & Co., a venture capital firm that holds a majoritystake in Serviscope.
"The company has grown dramatically over the last severalyears," Geisenheimer said. "Don has done a terrificjob in the sales and marketing arena, but we need to add strengthin (financial management)."
Serviscope has grown from four customers in 1990 to 630 lastyear. The company's revenues have risen accordingly, increasingfrom $100,000 in its first year to $13 million in 1993 (end-September).Serviscope is on a pace to bring in $20 million this year, andthe ISO turned profitable in the first quarter of 1994, accordingto Geisenheimer.
Southard joined Serviscope in 1991 after working for OEMs Philipsand Toshiba (SCAN 12/25/91). He will remain on Serviscope's boardof directors and will provide consulting to the ISO, accordingto Geisenheimer, who is also a former Philips medical executive.
Serviscope is negotiating with an unnamed medical imaging managerto take over the top spot, Geisenheimer said.
New Study Examines Short-Term Consistency of Large Language Models in Radiology
November 22nd 2024While GPT-4 demonstrated higher overall accuracy than other large language models in answering ACR Diagnostic in Training Exam multiple-choice questions, researchers noted an eight percent decrease in GPT-4’s accuracy rate from the first month to the third month of the study.
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.